Login to Your Account

Biovitrum Enters Obesity Deal With Glaxo Worth Up To $150M

By Cormac Sheridan

Wednesday, October 30, 2002
Biovitrum AB entered its first major commercial alliance, a deal potentially worth up to US$150 million with GlaxoSmithKline plc to develop and commercialize its collection of proprietary 5-hydroxytryptamine 2C receptor agonists for the treatment of obesity and other indications. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription